Overall rank by patents
#35,211
of 49,997 tracked assignees
USPTO 2015–2025 USPTO PatentsView US Corporation
Eolas Therapeutics, Inc
USPTO PatentsView assignee record - 7 granted patents across 3 technology areas, recorded in grant years 2016–2024. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: C07D (Heterocyclic Compounds).
The verdict
According to USPTO PatentsView, Eolas ranks #35,211 of 49,997 tracked US assignees by granted-patent volume, with 7 patents across 3 technology areas.
- #35,211
- of 49,997 US assignees by volume
- 44th percentile
- by Innovation Score (33.3/100)
- 22.1
- avg claims per patent
- -25%
- grant velocity, last 5 yrs
USPTO PatentsView assignee plate
Corpus R35211 · US Corporation #35,211 · 7 grants
GRANTS-MICRO · MID-PACK · PHOTO-FINISH · CPC-NARROW · INNOV-THIN · CLAIMS-DENSE · TYPE-USCORP · VEL-DOWN · BOOK-FULL
- GRANTS-MICRO 7 grants
- MID-PACK #35,211/49,997
- PHOTO-FINISH Energy Control
- CPC-NARROW C07D · 3 areas
- INNOV-THIN 33.3/100
- CLAIMS-DENSE 22.1 claims/avg
- TYPE-USCORP US Corporation
- VEL-DOWN -25% vel
- BOOK-FULL 10/10 fields
Nearest grant-volume peer: Energy Control Limited (±0 grants)
Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.
Innovation-score neighbourhood around Eolas
Lowest and highest poles plus nearest Innovation Score peers, not a full corpus board reprint.
- Qualcomm Incorporated · highest
Qualcomm Incorporated · highest
85 score
- Eolas Therapeutics · this assignee 33
Eolas Therapeutics · this assignee
33 score
- 3D Lighting… · lowest 7
3D Lighting… · lowest
7 score
What this shows Eolas's Innovation Score is 33.3/100 (44th percentile of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.
Where Eolas's grants concentrate
Eolas Therapeutics, Inc is a focused PatentsView assignee: 3 CPC subclasses with 100% of grants classified under C07D (Heterocyclic Compounds). Peak complete grant year is 2016 (2 grants) versus a trough of 1 in 2018. By volume, Eolas sits between Energy Control Limited and Epilog Imaging Systems, Inc..
Eolas's three-year grant acceleration
Eolas Therapeutics, Inc shows 2 grants in 2022–2024 against only 2 in 2019–2021. That prior window is too thin for a growth multiple (rename and spin-out assignees look artificially high when the baseline is near zero), so PlainPatent withholds a ranked acceleration claim here.
Who files at Eolas's volume?
Granted US patents 2015–2025 versus its nearest-ranked assignees by volume, this company marked ◀
- Energy Control
Energy Control Limited
7 patents
- Enpress
Enpress LLC
7 patents
- Enyo Pharma
Enyo Pharma
7 patents
- Enzymaster (Ningb…
Enzymaster (NINGBO) Bio-engineering Co., Ltd.
7 patents
- EON Reality
EON Reality, Inc.
7 patents
- Eospace
Eospace Inc.
7 patents
- Epileds
Epileds Technologies, Inc.
7 patents
- Epilog Imaging Sy…
Epilog Imaging Systems, Inc.
7 patents
- Eolas Therapeutics ◀
Eolas Therapeutics, Inc
7 patents
What this shows Eolas holds 7 patents at rank #35,150, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.
Companies ranked near Eolas
By rank, the assignees closest to #35,150 in granted patent volume.
- Energy Control Limited #35,146 · 7 patents
- Enpress LLC #35,147 · 7 patents
- Enyo Pharma #35,148 · 7 patents
- Enzymaster (NINGBO) Bio-engineering Co., Ltd. #35,149 · 7 patents
- EON Reality, Inc. #35,151 · 7 patents
- Eospace Inc. #35,152 · 7 patents
- Epileds Technologies, Inc. #35,153 · 7 patents
- Epilog Imaging Systems, Inc. #35,154 · 7 patents
Leaders in C07D (Heterocyclic Compounds)
Other assignees with the most granted patents in Eolas's primary technology class.
Eolas's Innovation Score vs. every tracked assignee
Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)
33 44th percentile higher than 44% of 49,997 US assignees
Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.
Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025
Grants by year
Teal-shaded recent years (2020–present) versus the 2016–2019 baseline. Full figures in the table below.
View data table
| Year | Patents Granted | Share of Period |
|---|---|---|
| 2016 | 2 | 28.6% |
| 2018 | 1 | 14.3% |
| 2019 | 1 | 14.3% |
| 2021 | 1 | 14.3% |
| 2022 | 1 | 14.3% |
| 2024 | 1 | 14.3% |
Which technologies does Eolas Therapeutics, Inc patent most?
Top 3 of 3 technology areas
What to do with this data
Eolas Therapeutics, Inc's patent record in context - here's where to go next.
- Eolas Therapeutics, Inc's lead technology class is C07D (Heterocyclic Compounds), 100% of its portfolio - see every assignee active in that class. Explore C07D
- Ranked #35,211 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
- Compare Eolas Therapeutics, Inc against Energy Control Limited, an assignee filing at a similar volume. Compare portfolios
- Innovation Score of 33.3/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated
Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.
Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.